160 likes | 278 Views
GTX-001 & GTX-002: A License To Cure?. Bio Genies, Inc. « …The 'holy grail' of autoimmune drugs -a small molecule compound taken orally that is as effective as targeted biologics. This compound would eclipse the currently biologic-driven autoimmune market. ».
E N D
GTX-001 & GTX-002: A License To Cure? Bio Genies, Inc. «…The 'holy grail' of autoimmune drugs -a small molecule compound taken orally that is as effective as targeted biologics. This compound would eclipse the currently biologic-driven autoimmune market.» J. Amarshi, A. Ehrlich, T. Fadel, J. Park, S. Zeller Friday November 20th 2009
IBD is the Manifestation of Chronic Inflammation of the GI Tract
GTX-001/002 Target Two Different Pathways Associated with IBD
Untreated/well-managed population Non-candidates for GTX Therapy Candidates for GTX Therapy GTX-001 and GTX-002 Target Different Potential Populations 2008 patient population (in thousands)
GTX-002 is Projected to be More Profitable, Even with Small Market Share Assumptions: 10% Discount Rate, 90% Patient Retention Rate
Pricing will be Driven by Comparable Therapies and Clinical Data
A Positive Return on Investment is Forecasted for GTX-002 R Assumptions: 10% Discount Rate, 90% Patient Retention Rate
Critical Milestones will Signal Continuation of GTX-002 Development
Licensing of GTX-002 is Recommended *GTX-002 is preferable to GTX-001 based on drug profile and market analysis -NPV of 1-13$ Billion w/ 10% Mkt Share *GTX-002 value will be driven by efficacy and toxicity profile in specific patient population subsets *We recommend pursuing GTX-002 for the broad treatment of UC and CD
References 1) Janeway’s Immunobiology, 2007 2) Goldstein et. al, Journal of Clinical Investigation 2003. 3) Mowat, AM. Nature Rev. Immuno. 2003. 4) MacDonald et. al, J. Clin. Pathol. 1990. 5) www.clinical trials.gov 6) M. Karin, A. Lin, Nature Rev. Immunology, 2002 7) M, Karin, Y. Yamammoto, Q.M. Wang, Nature Rev. Drug Discovery, 2004 8) http://www.reuters.com/article/pressRelease/idUS145077+30-Jun-2009+MW20090630